MY186475A - Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder - Google Patents

Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Info

Publication number
MY186475A
MY186475A MYPI2016703081A MYPI2016703081A MY186475A MY 186475 A MY186475 A MY 186475A MY PI2016703081 A MYPI2016703081 A MY PI2016703081A MY PI2016703081 A MYPI2016703081 A MY PI2016703081A MY 186475 A MY186475 A MY 186475A
Authority
MY
Malaysia
Prior art keywords
prevention
treatment
pyridazine derivatives
ataxic disorder
ataxic
Prior art date
Application number
MYPI2016703081A
Other languages
English (en)
Inventor
Sarah Almond
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY186475(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MY186475A publication Critical patent/MY186475A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2016703081A 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder MY186475A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
MY186475A true MY186475A (en) 2021-07-22

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016703081A MY186475A (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Country Status (31)

Country Link
US (1) US20170014407A1 (de)
EP (1) EP3113778B1 (de)
JP (1) JP6510549B2 (de)
KR (1) KR20160126081A (de)
CN (1) CN106102743A (de)
AU (1) AU2015225954B2 (de)
CA (1) CA2940342A1 (de)
CL (1) CL2016002151A1 (de)
CY (1) CY1120573T1 (de)
DK (1) DK3113778T3 (de)
EA (1) EA036438B1 (de)
ES (1) ES2676905T3 (de)
GB (1) GB201403944D0 (de)
GE (1) GEP20196984B (de)
HR (1) HRP20181082T1 (de)
IL (1) IL247435A0 (de)
LT (1) LT3113778T (de)
MA (1) MA39315A1 (de)
MX (1) MX2016010524A (de)
MY (1) MY186475A (de)
PH (1) PH12016501751A1 (de)
PL (1) PL3113778T3 (de)
PT (1) PT3113778T (de)
RS (1) RS57594B1 (de)
SG (1) SG11201607106YA (de)
SI (1) SI3113778T1 (de)
TR (1) TR201809537T4 (de)
TW (1) TW201534591A (de)
UA (1) UA123352C2 (de)
WO (1) WO2015132608A1 (de)
ZA (1) ZA201604611B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
CN111018790B (zh) 2014-04-29 2023-09-19 Fmc公司 哒嗪酮除草剂
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
CN111315725B (zh) 2017-06-30 2023-09-01 Fmc公司 作为除草剂的4-(3,4-二氢萘-1-基或2h-色烯-4-基)-5-羟基-2h-哒嗪-3-酮
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
WO2022187127A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262322T3 (es) * 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
PL3113778T3 (pl) 2018-11-30
CL2016002151A1 (es) 2016-12-30
SG11201607106YA (en) 2016-09-29
PH12016501751A1 (en) 2017-02-06
ZA201604611B (en) 2017-09-27
JP2017507156A (ja) 2017-03-16
EA201691566A1 (ru) 2016-12-30
JP6510549B2 (ja) 2019-05-08
PT3113778T (pt) 2018-07-11
CY1120573T1 (el) 2019-07-10
TR201809537T4 (tr) 2018-07-23
GB201403944D0 (en) 2014-04-23
AU2015225954A1 (en) 2016-07-07
ES2676905T3 (es) 2018-07-26
HRP20181082T1 (hr) 2018-09-07
CA2940342A1 (en) 2015-09-11
EP3113778B1 (de) 2018-06-06
EA036438B1 (ru) 2020-11-11
US20170014407A1 (en) 2017-01-19
AU2015225954B2 (en) 2020-06-18
DK3113778T3 (en) 2018-07-30
KR20160126081A (ko) 2016-11-01
LT3113778T (lt) 2018-08-27
WO2015132608A1 (en) 2015-09-11
CN106102743A (zh) 2016-11-09
TW201534591A (zh) 2015-09-16
RS57594B1 (sr) 2018-11-30
IL247435A0 (en) 2016-11-30
MX2016010524A (es) 2016-10-31
SI3113778T1 (en) 2018-08-31
GEP20196984B (en) 2019-06-25
EP3113778A1 (de) 2017-01-11
MA39315A1 (fr) 2017-09-29
UA123352C2 (uk) 2021-03-24

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
TW201613872A (en) IRAK4 inhibiting agents
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2016011992A (es) Derivados de piperidina-diona.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
MX2018004664A (es) Antagonistas de ep4.
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
JOP20190163B1 (ar) منشط nrf2
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12015500399A1 (en) Azaindolines
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.